

Symptomatic Patients Suspected of Eosinophilic Gastritis and/or Gastroenteritis Have Elevated Mucosal Mast Cell Counts Without Eosinophilia


Joseph A. Murray¹, Evan S. Dellon², Kathryn A. Peterson³, Gary W. Falk⁴, Mirna Chehade⁵, Robert M. Genta⁶, Nirmala Gonsalves⁷, Marc E. Rothenberg⁸, Paneez Khoury⁹, John Leung¹⁰, Adam C. Bledsoe¹, Camilla Shaw¹¹, Henrik S. Rasmussen¹¹, Bhupinder Singh¹¹, Alan T. Chang¹¹, Bradford A. Youngblood¹¹, Amol P. Kamboj¹¹, Ikuo Hirano⁷

¹Mayo Clinic Rochester, Rochester, MN; ²University of North Carolina, Chapel Hill, NC; ³University of Utah, Salt Lake City, UT; ⁴University of Pennsylvania, Philadelphia, PA; ⁵Icahn School of Medicine at Mount Sinai, NYC, NY; ⁶Baylor College of Medicine, Houston, TX; ⁷Northwestern University, Chicago, IL; ⁸Cincinnati Children's Hospital Medical Center, Cincinnati, OH; ⁹NIH/NIAID, Bethesda, MD; ¹⁰Tufts University Medical Center, Boston MC; ¹¹Allakos, Inc., Redwood City, CA

BACKGROUND


- Pathologic accumulation and over-activation of eosinophils are implicated in multiple chronic inflammatory diseases in the GI tract including eosinophilic esophagitis (EoE), gastritis (EG), gastroenteritis (EGE), and colitis - collectively termed eosinophilic gastrointestinal diseases (EGIDs)
- Patients with EGIDs have decreased quality of life due to debilitating symptoms such as dysphagia, abdominal pain, nausea, vomiting, and diarrhea
- While the pathogenesis of EGIDs has historically been thought to be driven by eosinophils, mast cells have also been shown to be elevated in EoE^{1,2}
- The role of mast cells in other EGIDs has yet to be established

Figure 1. Pathogenesis of EGIDs



- EG and EGE affect 45,000 - 50,000 patients in the US, though this number may be significantly underestimated³
- Current treatment options such as diet restriction and corticosteroids have limited efficacy and/or are inappropriate for chronic use
- There is a significant unmet need for novel targeted therapies

Figure 2. Antolimab (AK002) Mechanism of Action



- Siglec-8 is an inhibitory receptor selectively expressed on human eosinophils and mast cells, and therefore represents a novel target for the treatment of EGIDs
- Antolimab (AK002) is a novel, humanized, non-fucosylated IgG1 monoclonal antibody to Siglec-8
- Engagement of Siglec-8 receptor by antolimab triggers:
 - Antibody dependent cell mediated cytotoxicity (ADCC) against eosinophils (blood)
 - Inhibition of mast cells and apoptosis of tissue eosinophils (tissue)
- ENIGMA, a Phase 2 multi-center, randomized, double-blind, placebo-controlled study of antolimab, represents the largest clinical trial of patients with EG and/or EGE

OBJECTIVE

- To characterize symptomatic patients with suspected EG/EGE who did not meet histopathologic entry criteria for mucosal eosinophilia for a Phase 2 randomized, double-blind, placebo-controlled study of antolimab in patients with EG/EGE

METHODS

Figure 3. ENIGMA Screening Protocol






Figure 4. Counting Eosinophils and Mast Cells



- Eosinophils and mast cells were identified by H&E and immunohistochemistry (IHC), respectively. IHC was performed by staining with a mouse anti-human mast cell tryptase primary antibody (Clone AA1) followed by incubation with a peroxidase-labelled anti-mouse polymer secondary antibody and then counterstained with hematoxylin.
- Mast cells and eosinophils were counted in 5 separate non-overlapping high-power fields (hpf; area of 0.237 mm²) for each biopsy sample
- The patients qualified for study if the peak counts in 5 hpf in the stomach (or 3 hpf in the duodenum) was ≥30 eos/hpf
- The patients were determined to have elevated mast cells if the average of the peak counts in 5 hpf in the stomach (or 3 hpf in the duodenum) was ≥30 mast cells/hpf (normal mast cell counts from literature 12-20 /hpf⁴⁻⁸)

RESULTS

Figure 5. Patient Distribution



- 87 of 88 symptomatic patients had elevated mast cell counts

Table 1. Baseline Characteristics

| | ≥30 Eos; ≥30 MC ^a (n=72) | <30 Eos; ≥30 MC (n=16) |
|---|--|---------------------------|
| Age, Median Years (Range) | 42 (18-74) | 50 (19-78) |
| Female, n (%) | 43 (60%) | 11 (69%) |
| Race - White, n (%) | 66 (92%) | 14 (88%) |
| History of Atopy/Allergy ^b , n (%) | 56 (78%) | 4 (25%) |
| Blood Eos (cells/μL), Mean | 662 | 107 |
| Steroid Use n, (%) | 16 (22%) | 2 (13%) |

^a One patient with mast cells below 30 included
^b Medical history at screening of asthma, rhinitis, food allergy, atopic dermatitis, seasonal allergy, environmental allergy, or pollen allergy

Figure 6. Mast Cells Are Consistently Elevated in Stomach and Duodenal Biopsies in Clinically Suspected EGID Even in Absence of Tissue Eosinophilia





Figure 6. Data are plotted as box and whisker plots of peak mean cell count/hpf. The box plot represents the 25th and 75th percentiles, the internal horizontal line indicates the median and the T-bars indicate the minimum and maximum counts. The shaded gray bar indicates normal mast cell counts in the stomach & small intestine.⁴⁻⁸

^a One patient with mast cells below 30 included

Figure 7. Similar Symptom Profiles Between Groups Despite Low Eosinophils



^a One patient missing symptom data and did not enroll in ENIGMA; one patient with mast cells below 30 included

CONCLUSIONS/DISCUSSION

- Eighty-eight patients with suspected EG and/or EGE and active symptoms underwent endoscopy and biopsy: 72 of 88 met histologic eosinophil criteria for the study
- 87 of 88 (99%) patients screened had elevated mast cell counts in gastric and/or duodenal tissue biopsies
- Symptom profiles were similar between patients with and without tissue eosinophilia
- These data suggest that mast cells play an important pathogenic role in patients with suspected EG/EGE and raise the possibility of a non-eosinophilic condition driven by mast cells
- Due to antolimab's ability to inhibit mast cells, patients with elevated mast cells without tissue eosinophilia were offered to participate in an open label antolimab clinical trial (Data expected in 2020)

This study was funded by Allakos, Inc. and in part by Division of Intramural Research, NIAID, NIH

References:
1) Cabwell et al. J Allergy Clin Immunol. 2014.
2) Youngblood et al. JCI Insight. 2019.
3) Jensen ET, Martin CF, Kappelman MD, Dalton ES. J Pediatr Gastroenterol Nutr. 2016 Jun;62(1):36-42.
4) Helm et al. Am J Surg Pathol. 2007 Nov;31(11):1669-76.
5) Trzon et al. J Allergy Clin Immunol. 2010 Feb;125(2):AB162.
6) Walker et al. Aliment Pharmacol Ther. 2009 Apr 1;29(7):765-73.
7) Martinez et al. Gut. 2015 Aug;64(8):1160-8.
8) Doyle et al. Am J Surg Pathol. 2014 Jun;38(6):832-43.